Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer by Sjöblom, Liisa et al.
 
 
This document has been downloaded from  
TamPub – The Institutional Repository of University of Tampere 
 
 
Publisher's version http://urn.fi/URN:NBN:fi:uta-201603161320  
  
Author(s):  
Sjöblom, Liisa; Saramäki, Outi; Leinonen, Katri; Nättinen, Janika; 
Tolonen, Teemu; Wahlfors, Tiina; Nykter, Matti; Bova, Stephen G; 
Schleutker, Johanna; Tammela, Teuvo; Lilja, Hans; Visakorpi, Tapio 
Title:  Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer 
Year:  2016 
Journal 
Title:  Plos ONE 
Vol and 
number:  11 : 3  
Pages:  1-16 
ISSN:  1932-6203 
Discipline:  Cancers; Medical biotechnology 
School 
/Other Unit: BioMediTech; School of Medicine 
Item Type:  Journal Article 
Language:  en 
DOI:  http://dx.doi.org/10.1371/journal.pone.0150241  
URN:  URN:NBN:fi:uta-201603161320 
URL:  http://dx.doi.org/10.1371/journal.pone.0150241  
 
  
All material supplied via TamPub is protected by copyright and other intellectual 
property rights, and duplication or sale of all part of any of the repository collections 
is not permitted, except that material may be duplicated by you for your research use 
or educational purposes in electronic or print form. You must obtain permission for 
any other use. Electronic or print copies may not be offered, whether for sale or 
otherwise to anyone who is not an authorized user. 
 
 
  
  
  
RESEARCH ARTICLE
Microseminoprotein-Beta Expression in
Different Stages of Prostate Cancer
Liisa Sjöblom1,2, Outi Saramäki1,2, Matti Annala1, Katri Leinonen1,2, Janika Nättinen1,
Teemu Tolonen3, Tiina Wahlfors1, Matti Nykter1, G. Steven Bova1, Johanna Schleutker1,
Teuvo L. J. Tammela4,5, Hans Lilja1,6,7,8*, Tapio Visakorpi1,2
1 Prostate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech),
University of Tampere, Tampere, Finland, 2 Fimlab Laboratories, Tampere University Hospital, Tampere,
Finland, 3 Department of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland,
4 Prostate Cancer Research Center, School of Medicine, University of Tampere, Tampere, Finland,
5 Department of Urology, Tampere University Hospital, Tampere, Finland, 6 Departments of Laboratory
Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, United States of
America, 7 Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom,
8 Department of Translational Medicine, Lund University, Malmö, Sweden
* liljah@mskcc.org
Abstract
Microseminoprotein-beta (MSMB,MSMB) is an abundant secretory protein contributed by
the prostate, and is implicated as a prostate cancer (PC) biomarker based on observations
of its lower expression in cancerous cells compared with benign prostate epithelium. How-
ever, as the current literature on MSMB is inconsistent, we assessed the expression of
MSMB at the protein and mRNA levels in a comprehensive set of different clinical stages of
PC. Immunohistochemistry using monoclonal and polyclonal antibodies against MSMB
was used to study protein expression in tissue specimens representing prostatectomies (n
= 261) and in diagnostic needle biopsies from patients treated with androgen deprivation
therapy (ADT) (n = 100), and in locally recurrent castration-resistant PC (CRPC) (n = 105)
and CRPCmetastases (n = 113). The transcript levels ofMSMB, nuclear receptor co-acti-
vator 4 (NCOA4) andMSMB-NCOA4 fusion were examined by qRT-PCR in prostatectomy
samples and by RNA-sequencing in benign prostatic hyperplasia, PC, and CRPC samples.
We also measured serum MSMB levels and genotyped the single nucleotide polymorphism
rs10993994 using DNA from the blood of 369 PC patients and 903 controls. MSMB expres-
sion in PC (29% of prostatectomies and 21% of needle biopsies) was more frequent than in
CRPC (9% of locally recurrent CRPCs and 9% of CRPCmetastases) (p<0.0001). Detection
of MSMB protein was inversely correlated with the Gleason score in prostatectomy speci-
mens (p = 0.024). The read-throughMSMB-NCOA4 transcript was detected at very low lev-
els in PC. MSMB levels in serum were similar in cases of PC and controls but were
significantly associated with PC risk when adjusted for age at diagnosis and levels of free or
total PSA (p<0.001). Serum levels of MSMB in both PC patients and controls were signifi-
cantly associated with the rs10993994 genotype (p<0.0001). In conclusion, decreased
expression of MSMB parallels the clinical progression of PC and adjusted serumMSMB lev-
els are associated with PC risk.
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Introduction
Prostate cancer (PC) is the second most common cancer among men worldwide [1]. Measure-
ments of prostate specific antigen (PSA) in blood are widely used to detect men at PC-risk and
monitor men with PC. Due to low test-specificity at moderately elevated levels, indiscriminate
use of PSA-testing results in large number of unnecessary biopsies and over-diagnosis with a
consequent risk of overtreatment [2,3]. Hence, there is an urgent need for additional biomark-
ers that can provide enhanced specificity for the early detection of aggressive, lethal forms of
the disease.
Microseminoprotein-beta (MSMB, MSMB aka MSP, PSP94) is one of the three most abun-
dant proteins secreted by the prostate, along with PSA and prostatic acid phosphatase (PAP)
[4]. Several studies have shown higher MSMB expression in normal and benign prostate tissue
than in cancerous tissue [4–7]. Observations of higher MSMB expression in benign prostate
tissue prompted some investigators to suggest that MSMB has a tumor suppressive role in PC
[8]. Functional studies in vivo and in vitro also suggest a tumor suppressive role for MSMB [9].
Levels of MSMB in serum and urine have also been shown to be lower in PC patients than in
controls [10]. Positive MSMB expression has been reported to associate with favorable progno-
sis in needle biopsies [11] and loss of MSMB staining has been shown to be associated with
shorter time to biochemical recurrence in clinically localized PC [7]. By contrast, increased
MSMB expression in prostatectomy specimens has been suggested to be associated with unfa-
vorable disease outcomes [12]. Thus, the prognostic significance of MSMB expression in pros-
tate tissue remains controversial.
It has been shown that the serum level of MSMB is associated with a single nucleotide poly-
morphism (SNP) in rs10993994 in the promoter region ofMSMB, the gene encoding for
MSMB [13,14]. The T allele of the SNP rs10993994 has also been associated with PC risk
[15,16], which has been replicated in multiple studies [17–19]. Still, there is evidence of an
association between low levels of MSMB in serum and increased risk of PC regardless of the
rs10993994 genotype [20].
Published data on the regulation ofMSMB expression by androgens are inconsistent. Some
studies have shown that MSMB expression is independent of androgens [21,22]. However,
Dahlman and co-authors [23] found that theMSMB transcript and MSMB protein were both
significantly reduced after short-term androgen deprivation therapy (ADT). Enhancer of zeste
homologue-2 (EZH2), a known epigenetic silencer of gene expression, has been suggested to
silenceMSMB expression in advanced PC [24]. EZH2 has also been shown to be overexpressed
in late-stage PC [25].
TheMSMB gene is located on chromosome 10q11.2 [26]. A read-through fusion transcript
combiningMSMB with adjacent gene nuclear receptor co-activator 4 (NCOA4) has recently
been demonstrated by Nacu et al. [27] and confirmed in PC tissue and normal prostate tissue
by Lou et al. [28]. They also reported that theMSMB-NCOA4 fusion gene includes androgen
response elements (ARE) suggesting that the fusion gene could be regulated by androgens.
NCOA4 (aka ARA70) encodes an AR-associated protein that increases the transcriptional activ-
ity of AR in prostate cells [29]. It has been suggested thatMSMB-NCOA4 fusion could have a
role in PC due to the important roles ofMSMB in prostate tissue and of NCOA4 as an enhancer
of AR activity [27].
Due to the inconsistent data on the tissue expression of MSMB/MSMB in the prostate we
wanted to evaluate protein expression by immunohistochemistry (IHC) in comprehensive
cohorts of PC representing hormone-naïve localized and advanced disease, as well as locally
recurrent castration resistant PC (CRPC) and CRPC metastases. Additionally, transcript levels
ofMSMB, NCOA4 andMSMB-NCOA4 were studied to evaluate the significance of the read-
MSMB in Prostate Cancer
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through fusion transcript. Finally, serum levels of MSMB as well as rs10993994 genotype were
analyzed in a cohort of PC patients and controls.
Materials and Methods
Clinical tumor samples
Prostatectomy, needle biopsy and locally recurrent CRPC tissue specimens as well as serum
samples were obtained from Tampere University Hospital (TAUH). The samples were de-
identified and analyzed anonymously. The use of the prospectively collected samples was
approved by the Ethical committee of the Tampere University Hospital and the written
informed consent was obtained from the patients. The approval for use of retrospective collec-
tion of tissue samples without informed consent was obtained from the National Authority for
Medicolegal Affairs according to the Finnish law. The use of CRPC metastases was approved
by the Johns Hopkins Medicine Institutional Review Board, and written informed consent was
obtained from the subjects. All samples used for IHC were formalin-fixed, paraffin-embedded
(FFPE) samples. Tissue microarray (TMA) slides were created from the prostatectomy and
CRPC samples.
Prostatectomy samples. MSMB expression was evaluated with IHC in 261 prostatectomy
specimens. The characteristics of the cohort are shown in S1 Table. The same prostatectomy
specimens have previously been analyzed for Ki-67 and EZH2 [25]. Disease progression was
defined according to the blood PSA level, with biochemical recurrence (BCR) defined as a PSA
level 0.5 ng/ml in two consecutive blood draws.
Needle biopsy specimens. The needle biopsy cohort consisted of 99 diagnostic needle
biopsies from patients who subsequently received primary ADT. The Gleason score and treat-
ment information are presented in S2 Table. The same specimens have previously been ana-
lyzed for Ki-67- and EZH2-immunohistochemistry [30]. Disease progression was defined by
PSA measurements in two consecutive blood draws being 25% above nadir with an absolute
increase of2 ng/ml above nadir or development of new metastases [30,31].
Locally recurrent CRPC samples. Transurethral resection of the prostate (TURP) speci-
mens of 105 men with evidence of disease progression during ADT. Treatment information is
shown in S2 Table.
CRPC metastases. One hundred and thirteen CRPC metastases were collected from 32
patients who died of CRPC and underwent rapid autopsy. All patients had been treated with
ADT. The same metastases have also been analyzed for Ki-67 and EZH2 [25].
Prostatectomy cohort for qRT-PCR analyses. Seventy-six freshly frozen prostatectomy
specimens containing a minimum of 70% cancerous cells were used for qRT-PCR analysis. The
characteristics of the cohort are presented in S1 Table. TRI-reagent (Molecular Research Cen-
ter Inc., Cincinnati, OH, USA) was used to isolate total RNA from the freshly frozen clinical
samples and cell lines according to the manufacturer’s instructions.
RNA-sequencing cohorts. Data from freshly frozen tumor material from 12 benign pros-
tatic hyperplasia (BPH) samples, 28 hormone-naïve prostatectomy specimens and 13 CRPCs
[32] as well as 301 samples, including 251 cancerous samples and 45 adjacent normal tissue
samples from the Cancer Genome Atlas (TCGA)- cohort, were used for evaluating the expres-
sion levels ofMSMB, NCOA4 andMSMB-NCOA4.
Immunohistochemistry
All FFPE-samples were stained with a monoclonal MSMB antibody (ab19070; Abcam, Cam-
bridge, UK), and the prostatectomy- and CRPC-specimens were also stained with a polyclonal
MSMB antibody (4).For the staining, Power Vision+ Poly-HRP IHC kit (ImmunoLogic, AD,
MSMB in Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0150241 March 3, 2016 3 / 16
Duiven, Netherlands) was used according to the manufacturer’s instructions. Briefly, samples
were first deparaffinized and heat treated in pH 6 TriSodium citrate-buffer, containing 0.05%
Tween. Sections were incubated overnight with the diluted primary antibody. For the mouse-
derived commercial MSMB antibody, samples were blocked in post-blocking solution and
were then incubated with poly-HRP-solution. UltraVision Detection System (Thermo Fischer
Scientific Inc., Waltham, MA, USA) was used for the visualization of the bound primary anti-
body. Negative control without the primary antibody was included in all stainings. Slides were
scanned with Aperio ScanScope XT scanner (Aperio Technologies, Inc., Vista, CA, USA). Scor-
ing was performed in a blinded fashion using a virtual microscope (http://jvsmicroscope.uta.
fi). Intensity and percentage of the stained tumor area was evaluated. Expression of MSMB was
considered high when 20% or more of the tumor tissue was stained with an intensity of at least
1 on an intensity scale of 0–3. Mean values of Ki-67 defined low and high expression of Ki-67.
EZH2 expression was defined as high when>50% of the tumor cells were stained.
qRT-PCR forMSMB, NCOA4 andMSMB-NCOA4 and sequencing of
MSMB-NCOA4
The SYBR Green assay (Thermo Fischer Scientific Inc., Waltham, MA, USA) was used accord-
ing to the manufacturer’s protocol to detect the mRNA expression levels ofMSMB, NCOA4
and theMSMB-NCOA4 fusion. The sequences for the primers were obtained from Lou et al.
[28]. Thermal cycles were as follows: 95°C for 5 min., 95°C for 10 sec., annealing temperature
59°C (forMSMB), 62°C (for NCOA4) and 59.5°C (forMSMB-NCOA4) for 30 sec. and 72°C for
20 sec. The gene encoding the TATA- box binding protein (TBP) was used for normalization.
Finally, PCR -products were separated on 1% agarose gels to confirm the specificity of the reac-
tion. TheMSMB-NCOA4 fusion product was sequenced to confirm the presence of fusion. For
the sequencing, PCR -products were extracted from the gel and purified with a QIAquick kit
(QIAGEN Inc., Valencia, CA, USA) according to manufacturer’s protocol. Purified PCR-prod-
uct was cloned using a TOPO-TA cloning kit (Life Technologies, Carlsbad, CA, USA). A Big-
Dye terminator sequencing kit (Applied Biosystems, Foster City, CA, USA) was used for the
sequencing reactions. In data analyses, median values were used as a limit between high and
low expression of the mRNA levels ofMSMB, NCOA4 andMSMB-NCOA4.
Genotyping the SNP rs10993994 in germ-line DNA and measurement of
serumMSMB levels
Measurement of the serum MSMB levels and genotyping of rs10993994 were performed from
369 PC patients and 903 adult male age-matched (± two years) control subjects referred to the
Department of Urology without evidence of PC. The characteristics of the cases are presented
in S3 Table. The SNP rs10993994 was genotyped from the DNA samples using the Sequenom
MassARRAY (Sequenom Inc., San Diego, CA, USA) system at the Institute for Molecular Med-
icine Finland (FIMM). Immunoassay measurements of MSMB were conducted on the Auto-
Delfia 1235 automatic immunoassay system (PerkinElmer, Waltham, MA, USA) at Dr. Lilja’s
laboratory at Wallenberg Research Laboratories, Department of Translational Medicine, Lund
University, Skåne University Hospital, Malmö, Sweden as previously described [20,33,34]. Free
and total PSA were measured using the dual-label DELFIA Prostatus total/free PSA-Assay
(PerkinElmer, Turku, Finland) [35] calibrated against the WHO 96/670 (PSA-WHO) and
WHO 68/668 (free PSA-WHO) standards. All assay measurements were conducted with sam-
ples blinded to outcome.
MSMB in Prostate Cancer
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Statistical analyses
Fisher’s exact test, the Chi-squared test, the Mann-Whitney U-test and unpaired t-tests were
used to analyze the association between MSMB,MSMB, NCOA4 andMSMB-NCOA4 expres-
sion and different clinico-pathological and expression variables. Paired t-tests were used to
analyze differences between the expression levels ofMSMB, NCOA4 andMSMB-NCOA4.
Kaplan-Meier analysis of progression free survival was used to analyze the prognostic signifi-
cance of MSMB expression in different cohorts with the Mantel-Cox test. Fisher’s exact test
and the Kappa-test were applied when comparing results obtained using the commercial
MSMB antibody and those obtained with our polyclonal MSMB antibody. The Mann-Whitney
U-test was used to compare the serum levels of MSMB and PSA between PC patients and con-
trols. The data were analyzed with analysis of covariance (ANCOVA) to examine the associa-
tion of PC and serum MSMB levels, adjusted for age at diagnosis and free PSA or total PSA.
Both MSMB and PSA variables were log transformed. Logistic regression analysis was per-
formed, also with SPSS, to study the association between the serumMSMB level and PC risk
indicated by the Gleason score and the stage of PC. Spearman correlation was used to study
correlation between free, total and free to total PSA levels and the MSMB level in blood of
patients and controls. The Kruskal-Wallis test was used to analyze associations between serum
MSMB level and the genotype of the SNP rs10993994. Spearman correlation was used to ana-
lyze correlation between the serum MSMB level and age at diagnosis.
Results
Comparison of the monoclonal and polyclonal MSMB antibodies
Prostatectomy and locally recurrent CRPC samples were stained with both a rabbit polyclonal
MSMB antibody as described by Abrahamsson et al. [4] and a commercial monoclonal MSMB
antibody (ab19070, Abcam, Cambridge, UK). Both staining intensity and area of cancerous tis-
sue were assessed in scoring with MSMB expression defined as positive when 20% or more of
the tumor area had staining intensity from 1 to 3. Staining results with the monoclonal and
polyclonal antibodies were similar. Eighty percent of the prostatectomy samples manifesting
low level MSMB expression stained with the polyclonal MSMB antibody also showed low level
MSMB expression when stained with the monoclonal antibody (κ = 0.559, p<0.0001; Table 1).
In CRPC samples, the staining results were even more consistent between polyclonal and
monoclonal MSMB antibodies (κ = 0.77, p<0.0001; Table 1). Due to the consistent nature of
the staining, all other samples were stained only with the monoclonal antibody.
Prostatectomy specimens
MSMB was heterogeneously expressed in the cytoplasm of the malignant prostate epithelium
with distinct intensity differences observed in separate carcinomatous glands of the same speci-
men. Benign glands were commonly stained with high intensity, whereas cancerous glands
only rarely showed high staining intensity and MSMB expression was commonly low (Fig 1).
MSMB was expressed at a high level in 29% (75/261) of the cancerous tissue in prostatectomy
specimens. Cancerous lesions had staining intensity of 0 in 89% (166/186) of the prostatectomy
specimens, which was defined as low level expression of MSMB. MSMB expression tended to
be inversely associated with the Gleason score but not with the Gleason grade (p = 0.0544 and
0.1669, respectively, Table 2). High MSMB expression was observed in 52/178 cases (29%) of
the pT2 samples and 21/82 cases (26%) in pT3 samples (Table 2). There was no association
between MSMB expression and diagnostic PSA levels or between MSMB expression and age
(p = 0.8248; 0.2563, respectively; Table 2).
MSMB in Prostate Cancer
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Although there was no significant association between MSMB expression and EZH2 expres-
sion, EZH2 expression tended to be higher in samples expressing low levels of MSMB
(p = 0.1040; Table 2). There was no association between expression of MSMB and expression
of the proliferation marker Ki-67 (p = 0.2208; Table 2) or with time to biochemical recurrence
(p = 0.8997; S1 Fig).
Needle biopsy specimens
Tissue sections of diagnostic needle biopsy specimens represented a cohort of older patients
and/or more advanced disease at diagnosis than the prostatectomy cohort, and which received
primary ADT. Twenty-one out of 99 (21%) of the biopsy samples expressed MSMB at a high
level (Table2), with no association between MSMB expression and Gleason score or T-stage
(p = 0.7869; 0.8097, respectively; Table 2). Similarly, there was no association between MSMB
expression and the expression of EZH2 or Ki-67 (p = 0.4849 and 0.4055, respectively; Table 2).
Further, cases with high compared to low MSMB expression showed no difference in time to
biochemical progression by Kaplan-Meier analysis (p = 0.5621; S1 Fig).
Locally recurrent CRPC specimens
MSMB expression was high in only 9% (9/105) of locally recurrent CRPC samples (Table 2),
with no association between the expression of MSMB and EZH2 or Ki-67 expression
(p = 0.1024; 0.1545, respectively; Table 2).
CRPCmetastases
High MSMB expression was observed in 9% of the cases (3/32) (Table 2). One out of these
three patients had high MSMB expression in 1 out of 2 of his metastases. Another patient had
Table 1. Comparison of a monoclonal MSMB antibody and polyclonal MSMB antibody. Prostatectomy and locally recurrent CRPC samples were
stained with a rabbit polyclonal MSMB antibody (33) and a commercial monoclonal MSMB antibody (ab19070, Abcam, Cambridge, UK).
Variable Polyclonal MSMB antibody p κ
Low, n (%) High, n (%)
Prostatectomy specimens1, 2
Commercial monoclonal MSMB antibody: Low 122(80) 31(20)
Commercial monoclonal MSMB antibody: High 12(18) 53(82) <0.0001 0.559
CRPC specimens1, 2
Commercial monoclonal MSMB antibody: Low 82(99) 1(1)
Commercial monoclonal MSMB antibody: High 3(27) 8(73) <0.0001 0.77
1Fisher’s exact test
2Kappa-test.
doi:10.1371/journal.pone.0150241.t001
Fig 1. MSMB staining using amonoclonal MSMB antibody (ab19070, Abcam, Cambridge, UK). (A)
High, medium and low MSMB staining in normal prostate tissue. (B) High, medium and low MSMB staining in
prostate cancer tissue.
doi:10.1371/journal.pone.0150241.g001
MSMB in Prostate Cancer
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Table 2. Association of MSMB expression with clinicopathological variables and expression of EZH2 and Ki-67. These results are based on IHC-
analysis of different cohorts.
Variable MSMB expression p
Low High
Prostatectomy specimens n (%) 186 (71) 75 (29)
Needle biopsy specimens n (%) 79 (79) 21 (21)
Locally recurrent CRPCs n (%) 96 (91) 9 (9)
CRPC metastases (patients) n (%)1 29 (91) 3 (9) <0.0001
CRPC metastases (samples) n (%) 106 (94) 7 (6)
Prostatectomy specimens:
Gleason score, n (%)1
6 60 (63) 36 (37)
3+4 (7) 62 (73) 23 (27)
4+3 (7) 33 (77) 10 (23)
8 29 (83) 5 (15) 0.0544
Gleason grade, n (%)1
2–3 126 (68) 60 (32)
4 48 (77) 14 (23)
5 8 (89) 1 (11) 0.1669
pT- stage, n (%)2
pT2 126 (71) 52 (29)
pT3 61 (74) 21 (26) 0.6562
PSA ng/ml (mean ± SD)3 14.1 ± 11.4 17.45 ± 30.6 0.8248
Age (mean ± SD)4 63.2 ± 0.4 62.4 ± 0.7 0.2563
EZH2 (mean ± SD)3 37.9 ± 24.0 32.4 ± 23.2 0.1040
Ki-67 (mean ± SD)3 11.1 ± 14.2 9.0 ± 11.6 0.2208
Needle biopsy specimens:
Gleason score, n (%)1
6 20 (83) 4 (17)
7 33 (79) 9 (21)
8 25 (76) 8 (24) 0.7869
T stage n (%)2
T2 40 (80) 10 (20)
T3 38 (78) 11 (22) 0.8097
PSA ng/ml (mean ± SD)3 5.4 ± 17.1 2.1 ± 2.4 0.3078
Age (mean ± SD)4 73.2 ± 0.79 71.4 ± 1.6 0.3169
Tumor area% (mean ± SD)5 30.5 ± 3.0 27.7 ± 5.6 0.6617
EZH2 (mean ± SD)3 24.3 ± 19.7 20.7 ± 18.6 0.4849
Ki-67 (mean ± SD)3 8.9 ± 0.7 7.6 ± 1.3 0.4055
Locally recurrent CRPCs:
EZH2 (mean ± SD)3 56.8 ± 27.3 42.6 ± 26.3 0.1024
Ki-67 (mean ± SD)3 18.4 ± 14.7 11.1 ± 6.6 0.1545
CRPC metastases:
EZH2 (mean ± SD)3 29.6 ± 24.9 36.5 ± 20 0.3295
Ki-67 (mean ± SD)3 11.5 ± 13.4 12.9 ± 7.5 0.2412
1χ2 test
2Fisher’s exact test
3Mann Whitney test
4Unpaired t test
5Unpaired t test with Welch correction. Low MSMB expression: <20% of the cancer tissue was positively stained (with intensity 1–3). High MSMB
expression: 20% of the cancer tissue was positively stained (with intensity 1–3). EZH2 and Ki-67 were scored according to the stained area of the tumor
tissue.
doi:10.1371/journal.pone.0150241.t002
MSMB in Prostate Cancer
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high MSMB expression in 3 of 5 of the metastases, and the third patient in 3 of 4 of the metas-
tases. MSMB was expressed at a high level in 6% (7/112) of all the metastases (Table 2). MSMB
expression was not associated with the expression of Ki67 or with EZH2 (p = 0.2412 and
0.3295, respectively; Table 2).
MSMB, NCOA4 andMSMB-NCOA4 fusion
First, transcripts ofMSMB, NCOA4 and the fusion ofMSMB-NCOA4 were measured by
qRT-PCR in RNA isolated from cancerous tissue in a cohort of patients with clinically localized
PC treated with prostatectomy (n = 76). The data had a non-Gaussian distribution, with most
samples showing below- averageMSMB expression and only 25% (19/76) of samples manifest-
ing MSMB-expression above average. NCOA4 was expressed at a high level in 41% (31/76) of
the samples and high levels ofMSMB-NCOA4 fusion was found in 32% (23/73) of the samples
(Table 3). The expression ofMSMB-NCOA4 fusion transcripts was correlated with the expres-
sion ofMSMB (Pearson r = 0.5092, p<0.0001; Fig 2).MSMB expression tended to be lower at
higher tumor grade, but the expression levels ofMSMB, NCOA4, and theMSMB-NCOA4
fusion transcript were not significantly associated with the Gleason score (p = 0.0913; 0.2577;
and 0.1963, respectively), pT-stage (p = 0.2760; 0.4819; and 1.000, respectively; Table 3), or
time to biochemical recurrence (p = 0.3862; 0.4126; and 0.5940, respectively; S2 Fig).
Second, the detection ofMSMB, NCOA4 andMSMB-NCOA4 fusion transcripts was
assessed using RNA-seq in two cohorts; one containing 12 BPH, 28 hormone-naïve PC, and 13
CRPC samples [32], as well as a second TCGA-cohort consisting of 301 prostate adenocarci-
noma tumors. Overall, the expression ofMSMB-NCOA4 was low and expression was observed
more frequently in PC than in BPH tissue, although low levels of expression were detected in 2
of the 12 BPH samples (Fig 3). In the sample that expressedMSMB-NCOA4 at the highest
level, only 2.2% of the transcripts starting from theMSMB promoter formed a transcript with
NCOA4 (Fig 3B). NCOA4 was expressed at a significantly lower level thanMSMB in both
cohorts (Fig 3 and S3 Fig).
Table 3. Association ofMSMB,NCOA4 andMSMB-NCOA4 expression and the Gleason score, pT- stage and age. These results are based on
Q-RT-PCR-analysis. Means of the normalized values were used as a cut-off value between high and low expression ofMSMB, NCOA4 andMSMB-NCOA4.
Age refers to age at diagnosis.
Variable MSMB expression p NCOA4 expression p MSMB-NCOA4
expression
p
Low High Low High Low High
Prostatectomy specimens (%)1 57 (75) 19 (25) 45 (59) 31 (41) 50 (68) 23 (32) 0.0003
Gleason score, n (%)2
6 24 (86) 4 (14) 16 (57) 12 (43) 22 (73) 8 (27)
7 18 (62) 11 (38) 20 (69) 9 (31) 15 (56) 12 (44)
8 10 (83) 2 (17) 0.0913 10 (83) 2 (17) 0.2577 9 (82) 2 (18) 0.1963
pT- stage, n (%)3
pT2 30 (68) 14 (32) 24 (55) 20 (45) 30 (70) 13 (30)
pT3 22 (81) 5 (19) 0.2760 19 (63) 11 (37) 0.4819 19 (68) 9 (32) 1.000
Age (mean ± SD)4 62.0 ± 0.7 61.5 ± 1.6 0.7511 61.7 ± 0.9 61.8 ± 0.8 0.9071 61.9 ± 0.8 61.8 ± 1.3 0.9089
1 One-way analysis of variance
2χ2 test
3Fisher’s exact test
4Unpaired t test.
doi:10.1371/journal.pone.0150241.t003
MSMB in Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0150241 March 3, 2016 8 / 16
SerumMSMB levels and SNP rs10993994
There was no significant correlation between MSMB levels in serum and age at diagnosis of PC
patients (Spearman r = 0.1550) or age at blood draw among controls (Spearman r = 0.1876; S4
Fig). In PC cases, the median level of MSMB in serum (23.0 ng/ml; interquartile range (IQR)
15.9) was not different (p = 0.2422) from that in controls (21.8 ng/ml; IQR 15.3; Table 4). How-
ever, when adjusted by age and free or total PSA at diagnosis, there was a significant association
between PC risk and the serum levels of MSMB in the covariance analysis (p<0.001; Table 5).
MSMB levels were higher in controls (the mean MSMB level was 29.7 ng/ml when adjusted by
Fig 2. Correlation ofMSMB andMSMB-NCOA4 expression according to qRT-PCR.MSMB expression
was positively correlated with expression ofMSMB-NCOA4.
doi:10.1371/journal.pone.0150241.g002
Fig 3. RNA-sequencing data of expression ofMSMB,NCOA4 andMSMB-NCOA4 in BPH, PC and
CRPC samples. (A)MSMBwas expressed at higher level thanNCOA4. (B) Lower panel shows the
percentage of theMSMB-NCOA4 reads from the total reads ofMSMB andMSMB-NCOA4. NCOA4was
expressed at lower level thanMSMB. The fusion gene expression portion was 2.2% at highest, out of the
sum of MSMB and MSMB-NCOA4 reads. Y-axis represents normalized read count.
doi:10.1371/journal.pone.0150241.g003
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age and total PSA at diagnosis and 29.2 ng/ml when adjusted by age and free PSA at diagnosis)
compared to PC patients (the meanMSMB level was 21.1 ng/ml when adjusted by age and total
PSA at diagnosis and 22.4 ng/ml when it was adjusted by age and free PSA at diagnosis)
(Table 5). Further, the serumMSMB level was associated with risk indicated by the Gleason
score and with clinical stage at diagnosis (S4 Table), with the association remaining significant in
non-metastatic or metastatic cases alone. Additionally, PC patients had a significantly lower free/
total PSA ratio compared with controls (p<0.0001; Table 4). There was a statistically significant
albeit weak positive correlation between levels of MSMB and free PSA as well as between MSMB
and total PSA in serum from cancer cases (Spearman r = 0.3990 and 0.3200, respectively) and in
controls (Spearman r = 0.3421 and 0.2710, respectively), p<0.0001 in all (S5 Fig), and significant
association between the free-to-total PSA ratio and the serum levels of MSMB in cases and con-
trols (Spearman r = 0.2142; r = 0.1351, respectively), p<0.0001 in all (S5 Fig).
Among the PC patients, the MSMB levels in serum were not associated with Gleason score
in prostatectomy or biopsy specimens (p = 0.6621; 0.819, respectively; Table 6), but serum
MSMB levels and pT-stage (p = 0.0288) and age at diagnosis (p = 0.0452) tended to be weakly
associated in prostatectomy cases (Table 6). Kaplan-Meier analysis showed no association
between the serumMSMB level and time to biochemical recurrence in patients treated with
prostatectomy or radiation therapy (p = 0.1396; 0.1925, respectively; S6 Fig) or hormone-
treated patients (p = 0.2070; S6 Fig).
In contrast, there was a very strong association between low MSMB levels in serum and TT
risk genotype of the SNP rs10993994 of both cancer cases and controls (p<0.0001; 0.0001,
respectively; Fig 4). However, the SNP rs10993994 was not associated with Gleason score at
Table 4. Characteristics of PC patients and controls of blood sample cohort.
Biomarker
Mean (±SD) case subjects / control subjects Median (IQR) case subjects / control subjects p
MSMB (ng/ml)1 27.8 (± 24.4) / 26.5 (± 24.7) 22.9 (15.9) / 21.8 (15.3) 0.2422
Free/ Total PSA (ng/ml)1 17.4 (± 11.4) / 28.4 (± 12.8) 14.7 (9.15) /26.4 (15.7) <0.0001
Age1, 2 68.1 (± 8.3) / 64.6 (± 9.3) 68 (10.7) / 64 (11) <0.0001
1Mann Whitney test
2Age of the cancer cases refers to age at diagnosis and age of the controls refers to age at the time when the blood sample was taken.
doi:10.1371/journal.pone.0150241.t004
Table 5. Characteristics of PC patients and controls of blood sample cohort adjusted by covariance analysis.
Characteristic Cases Controls
Mean SD Mean SD p***
Age at diagnosis 68.1 0.5 64.6 0.3 <0.001
MSMB * 21.1 1.5 29.7 0.9 <0.001
MSMB # 22.4 1.4 29.2 0.9 <0.001
Total PSA ** 22.5 3.1 4.6 1.9 <0.001
Free PSA ** 3.6 0.4 1.2 0.3 <0.001
Free to total PSA ** 0.2 0.01 0.3 0.004 <0.001
* means adjusted by covariance analysis for age at diagnosis, total PSA (log2-transformed)
# means adjusted by covariance analysis for age at diagnosis, free PSA (log2-transformed)
** means adjusted by covariance analysis for age at diagnosis, MSMB (log2-transformed)
*** F test of case-control differences from covariance analysis.
doi:10.1371/journal.pone.0150241.t005
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biopsy or prostatectomy specimens or with pT-stage at prostatectomy (p = 0.7959; 0.4683;
0.3584, respectively; Table 7). Although the frequency of TT genotype tended to be slightly
higher in cancer cases (15%) compared with controls (12%), there was no association of the
rs10993994 genotype and cancer risk in this cohort (p = 0.5114; Table 7).
Discussion
In this paper, we studied the potential role of MSMB/MSMB/MSMB-NCOA4 as PC biomarkers
in cohorts corresponding to different stages of PC from early to advanced disease. We showed
that MSMB expression is reduced in more advanced PC, being lowest in the CRPC. The low
MSMB protein levels in CRPC were consistent with our RNA-seq data indicating lowMSMB
transcript levels in the CRPC compared to PC samples. The finding of decreased expression of
Table 6. Association of serumMSMBwith the Gleason score, pT-stage and age at diagnosis.
Variable Level of serum MSMB p
Low, n (%) High, n (%)
Gleason score (biopsy), n (%)1
6 82(50) 82(50)
7 55(48) 59(52)
8 33(53) 29(47) 0.8194
Prostatectomy-treated patients
Gleason score, n (%)1
6 15(44) 19(56)
7 37(54) 32(48)
8 8(50) 8(50) 0.6621
pT- stage, n (%)2
pT2 37(44) 47(56)
pT3 24(67) 12(33) 0.0288
Age (mean ± SD)3 67 ± 7.5 69 ± 8.9 0.0452
1Chi-square test
2 Fisher’s exact test
3Unpaired t test, Median (Gleason score: biopsy 23.5 ng/ml; prostatectomy: 21 ng/ml, pT-stage: 20.9 ng/ml) was used as a limit between low and high
expression of MSMB.
doi:10.1371/journal.pone.0150241.t006
Fig 4. Genotype of SNP rs10993994 and MSMB level in blood of (A) PC patients and (B) controls. Lower
MSMB level was associated with T-allele of the SNP rs10993994. Kruskal-Wallis test was used to compare
the different groups. Lines represents the mean MSMB level of the different genotypes. *** denotes
p<0.0001.
doi:10.1371/journal.pone.0150241.g004
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MSMB/MSMB in PC compared with non-malignant prostate, as well as association of the loss
of expression with more advanced and higher-Gleason-score disease, is consistent with several
previous publications [5–7]. However, CRPC cases have not been thoroughly studied before.
Dahlman et al., [23] studied MSMB expression in 3 CRPC metastases and found lowMSMB
transcript levels. Here, we showed that both transcript and MSMB protein levels are low in
CRPC with only 9% of the CRPC cases expressing MSMB.
In our study, MSMB protein or mRNA levels were not associated with prognosis in prosta-
tectomy or ADT- treated patients. Some previous publications have shown an association
between low MSMB and poor prognosis in PC [7,11], whereas others demonstrated high
MSMB orMSMB transcript levels and poor prognosis [12,36]. There may be several reasons
for the discordant findings. Patient cohorts vary. Here, we used three cohorts: (a) a prostatec-
tomy cohort of 261 cases with a mean follow-up of 7.3 years, (b) a prostatectomy cohort of 76
cases with a mean follow-up of 5.2 years and (c) a cohort of primarily ADT-treated patients
with a mean follow-up of 3.6 years. Cohorts a and c were used for immunohistochemical detec-
tion of MSMB protein and cohort b for qRT-PCR measurement ofMSMB transcript. Consis-
tently, none of the cohorts showed prognostic value for MSMB/MSMB. One putative variable
is the antibody used for immunostaining. We tested two commonly used antibodies, a mono-
clonal antibody and a polyclonal one. They gave highly concordant staining patterns. Thus, the
antibodies are likely not the cause of the discrepant data.
A read-through fusion transcript of NCOA4 andMSMB has recently been demonstrated in
some prostate cancers [27,28]. Thus, we aimed to measure the expression of the fusion tran-
script in clinical specimens. We found thatMSMB-NCOA4 expression was correlated with
MSMB expression and not associated with the prognosis of prostatectomy-treated patients.
Based on RNA-seq data, the expression level of theMSMB-NCOA4 fusion was also very low,
even in the sample expressing the fusion transcript at the highest level. Thus, the clinical rele-
vance of the fusion gene remains unknown. Read-through transcripts are relatively common in
cancer, but often their functional significance remains unknown [37].
Table 7. Association of the SNP rs10993994 with the Gleason score of the biopsy and prostatectomy
specimens and pT-stage.
Variable rs10993994 genotype
CC TC TT p
Cancer cases, n (%)2 154 (42) 160 (43) 54 (15)
Controls, n (%) 394 (44) 396 (44) 111 (12) 0.5114
Gleason score (biopsy), n (%)1
6 64 (41) 73 (46) 21 (13)
7 49 (43) 49 (43) 16 (14)
8 25 (40) 25 (40) 12 (20) 0.7959
Prostatectomy-treated patients
Gleason score, n (%)1
6 11 (32) 17 (50) 6 (18)
7 31 (45) 31 (45) 7 (10)
8 9 (56) 6 (38) 1 (6) 0.4683
pT- stage, n (%)2
pT2 5 (42) 7 (58) 0 (0)
pT3 42 (41) 46 (45) 14 (14) 0.3584
1Chi-square test
2Fisher’s exact test.
doi:10.1371/journal.pone.0150241.t007
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Beke et al. [24] have suggested thatMSMB is a target for EZH2. They showed thatMSMB
transcription is diminished by EZH2 via tri-methylation of H3K27. We studied the association
between the expression of MSMB and EZH2 in prostatectomy, needle biopsy and CRPC sam-
ples and saw a slight trend of higher EZH2 expression in samples where MSMB expression was
low (Table 2). However, no significant association was observed. Thus, it is likely that other
mechanisms lead to decreased expression of MSMB in CRPC.
We did not found a significant difference in serum MSMB levels between the cancer cases
and the controls when the comparison was performed without adjustment with age and free or
total PSA. In fact, an average MSMB level was slightly higher in sera of cases compared to con-
trols. However, when adjusted for age at diagnosis and free or total PSA, the serum MSMB
level was higher in the blood of controls than in PC patients. This result is consistent with
those obtained in the study by Haiman et al. [20].
CT and TT genotypes of the SNP rs10993994 were associated with lower MSMB level in
serum both in PC cases and controls, consistent with previous studies [13,14,20,38]. In the
study by Xu et al. [14], the T allele of rs10993994 was also associated with PC risk. In our study
we did not see the association. More studies are warranted to investigate the potential role of
serumMSMB and rs10993994 genotype in detection of PC.
In conclusion, the study confirms that MSMB expression is reduced in PC and is lowest in
CRPC. The low serum level of MSMB was also associated with the risk of PC when adjusted for
age and PSA. In the future, it will be important to study whether MSMB could be used together
with other biomarkers to detect clinically significant PC. In addition, new reagents to detect
different forms of MSMB, such as the CRISP3-bound form [39], are urgently needed.
Supporting Information
S1 Fig. Progression-free survival of prostatectomy (A) and ADT-treated (B) patients accord-
ing to the MSMB immunostaining. Low MSMB expression:<20% of the cancer tissue was pos-
itively stained (with intensity 1–3). High MSMB expression:20% of the cancer tissue was
positively stained (with intensity 1–3). Mantel-Cox test was used to discover the p-values.
(TIF)
S2 Fig. Progression-free survival of prostatectomy-treated patients according to (A)MSMB,
(B) NCOA4 and (C)MSMB-NCOA4 expression. Expressions were measured with qRT-PCR.
The median value was used as a cut-off point between high and low expression. The p-values
were discovered by Mantel-Cox test.
(TIF)
S3 Fig. RNA-sequencing data of expression ofMSMB, NCOA4 andMSMB-NCOA4 in
TCGA-cohort. TCGA-cohort included 301 prostate adenocarcinoma tumors. NCOA4 was
expressed at lower level thanMSMB.MSMB-NCOA4 expression was low compared to expres-
sion ofMSMB. Y-axis represents normalized read count.
(TIFF)
S4 Fig. Correlation of serumMSMB level with age of (A) PC cases and (B) controls. In figure
A, age indicates age at diagnosis. In figure B, age indicates the time when blood sample was
taken.
(TIF)
S5 Fig. Correlation of serumMSMB level with PSA-levels. Correlation of serumMSMB level
with free and total PSA levels of (A and B) cancer cases and (C and D) controls. (E) and (F)
illustrates correlation between free to total PSA level and MSMB level in blood of (E) patients
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and (F) controls.
(TIF)
S6 Fig. Progression-free survival of (A) prostatectomy-, (B) radiation- and (C) ADT-treated
patients according to serumMSMB. The median level was used as a cut-off value for low and
high level. Mantel-Cox test was used to discover the p-values.
(TIF)
S1 Table. Characteristics of prostatectomy specimens used in IHC (n = 261) and qRT-PCR
(n = 76).
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S2 Table. Characteristics of 99 needle biopsy specimens and 105 locally recurrent CRPCs
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